ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu +23 more
wiley +1 more source
AAV vectors for long-term gene therapy of hemophilia B: Are we there yet? [PDF]
Srivastava A.
europepmc +1 more source
Enhancing Adeno‐Associated Virus 2 Capsid Engineering Through Co‐Evolutionary Coupling
ABSTRACT Adeno‐associated virus (AAV) has emerged as a leading platform for gene therapy. However, to unlock the full potential, their manufacturing yields, stability, and efficacy must all be improved. Rational design is limited by poor predictability and the potential impact of mutations on multiple important vector properties.
Sirimar Laosinwattana +4 more
wiley +1 more source
Characterization of AAV vectors: A review of analytical techniques and critical quality attributes. [PDF]
Kontogiannis T +6 more
europepmc +1 more source
Purification and concentration of model viruses using single‐pass tangential flow filtration
Single‐pass TFF was developed for an enveloped and non‐enveloped virus for use in continuous downstream purification processes. Enveloped virus was concentrated and purified. Abstract The vaccine and viral vector industry is growing at an accelerated rate.
Luis Alberto Mejía‐Manzano +6 more
wiley +1 more source
Spatial genomics of AAV vectors reveals mechanism of transcriptional crosstalk that enables targeted delivery of large genetic cargo. [PDF]
Coughlin GM +10 more
europepmc +1 more source
Status and future of recombinant adeno‐associated virus vector manufacturing
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley +1 more source
Endothelial-to-mesenchymal transition enhances permissiveness to AAV vectors in cardiac endothelial cells. [PDF]
Volf N +10 more
europepmc +1 more source
Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing +2 more
wiley +1 more source
Engineered nanoparticles promote cardiac tropism of AAV vectors. [PDF]
Switala L +7 more
europepmc +1 more source

